Fiera Capital Corp Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Fiera Capital Corp increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 93.9% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 53,804 shares of the biopharmaceutical company’s stock after buying an additional 26,061 shares during the period. Fiera Capital Corp’s holdings in Alnylam Pharmaceuticals were worth $24,535,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Thematics Asset Management bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $1,995,000. Mediolanum International Funds Ltd bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $11,389,000. Teacher Retirement System of Texas increased its stake in shares of Alnylam Pharmaceuticals by 3.2% in the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after buying an additional 1,123 shares during the period. Rakuten Investment Management Inc. bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $14,205,000. Finally, Generali Asset Management SPA SGR raised its holdings in Alnylam Pharmaceuticals by 6,368.0% during the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 3,184 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,959 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the completion of the transaction, the executive vice president owned 31,769 shares in the company, valued at approximately $9,850,931.52. This represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares of the company’s stock, valued at $20,852,324.55. This represents a 4.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,578 shares of company stock worth $12,416,105 over the last quarter. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ALNY shares. Chardan Capital cut their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Piper Sandler restated an “overweight” rating and set a $489.00 price target (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Finally, Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Company reported ~ $3.0B in 2025 revenue (≈81% YoY) with Q4 net product revenue of $995M and a 151% surge in the TTR franchise — evidence of accelerating commercial momentum that supports longer‑term growth expectations. Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
• Positive Sentiment: Canaccord Genuity raised its price target to $429, signaling stronger upside in analysts’ models and providing support for the stock’s valuation case. Canaccord Genuity Group Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $429.00
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, and Freedom Capital upgraded ALNY to “Strong Buy” (reported via Zacks), adding buy‑side endorsement that could attract momentum investors. HC Wainwright Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) Freedom Capital Upgrade via Zacks
• Neutral Sentiment: Some analysts trimmed targets after the latest reports while still expressing confidence in 2026 growth — a mixed read that leaves upside intact but tempers near‑term estimates. Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth
• Neutral Sentiment: Independent valuation pieces highlight a divergence between recent share‑price performance and bullish fair‑value models — useful context for investors debating entry points. Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models
• Negative Sentiment: Insider selling picked up this week: an EVP sold ~$607,447 of stock, and two other officers (Kevin Joseph Fitzgerald and Pushkal Garg) sold shares (2,041 and 2,242 shares respectively). Insider sales can create short‑term sentiment pressure even if they are routine. Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $607,446.72 in Stock Kevin Joseph Fitzgerald Sells 2,041 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Pushkal Garg Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $336.19 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The stock has a market capitalization of $44.59 billion, a P/E ratio of 196.60 and a beta of 0.35. The company’s 50-day moving average is $366.89 and its 200 day moving average is $422.44. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the previous year, the firm posted ($0.65) earnings per share. The business’s revenue was up 84.9% compared to the same quarter last year. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.